Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
September 12, 2024 07:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
September 09, 2024 06:41 ET
|
Quantexa
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024 16:01 ET
|
Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Quantexa Recognized as a “Luminary” in Celent’s 2024 Insurance Fraud Detection Solutions Report
September 04, 2024 05:32 ET
|
Quantexa
Quantexa announced that its Fraud Detection solution has been awarded “Luminary” status in Celent’s 2024 Insurance Fraud Detection Solutions Report.
Senti Bio to Participate in Upcoming Investor Conferences
September 03, 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Vor Bio to Participate in Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
August 13, 2024 16:05 ET
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
August 05, 2024 08:05 ET
|
Senti Biosciences, Inc.
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
USA Bank Secrecy Act (BSA) Compliance Mandates Webinar: Latest Regulatory Developments for Financial Institutions (ON-DEMAND)
July 09, 2024 04:35 ET
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "BSA Important Issues: new mandates, requirements, and recommendations" report has been added to ResearchAndMarkets.com's offering. The landscape of...
FFIEC Bank Secrecy Act/Anti-Money Laundering Examination Manual Webinar: What Compliance Officers Really Need to Know? (ON-DEMAND)
July 09, 2024 04:29 ET
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?" training has been added to ResearchAndMarkets.com's offering.This...